Cargando…
Oncogenic cancer/testis antigens: prime candidates for immunotherapy
Recent developments have set the stage for immunotherapy as a supplement to conventional cancer treatment. Consequently, a significant effort is required to further improve efficacy and specificity, particularly the identification of optimal therapeutic targets for clinical testing. Cancer/testis an...
Autores principales: | Gjerstorff, Morten F., Andersen, Mads H., Ditzel, Henrik J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599236/ https://www.ncbi.nlm.nih.gov/pubmed/26158218 |
Ejemplares similares
-
The role of GAGE cancer/testis antigen in metastasis: the jury is still out
por: Gjerstorff, Morten Frier, et al.
Publicado: (2016) -
Lack of ADAM2, CALR3 and SAGE1 Cancer/Testis Antigen Expression in Lung and Breast Cancer
por: Maheswaran, Emeaga, et al.
Publicado: (2015) -
Analysis of GAGE, NY-ESO-1 and SP17 cancer/testis antigen expression in early stage non-small cell lung carcinoma
por: Gjerstorff, Morten F, et al.
Publicado: (2013) -
CAR T-Cell Cancer Therapy Targeting Surface Cancer/Testis Antigens
por: Jakobsen, Mie K., et al.
Publicado: (2020) -
Cancer testis antigen and immunotherapy
por: Krishnadas, Deepa Kolaseri, et al.
Publicado: (2013)